Last reviewed · How we verify
NDA vs BLA
NDA — small molecules
A New Drug Application (NDA) is filed under section 505 of the Federal Food, Drug, and Cosmetic Act. It covers chemically-synthesised small molecules (typically <1kDa). Approval grants 5 years of New Chemical Entity (NCE) data exclusivity. Generic competition arrives via Abbreviated NDA (ANDA) under the Hatch-Waxman framework, typically within 6 months of patent + exclusivity expiry.
BLA — biologics
A Biologics License Application (BLA) is filed under section 351 of the Public Health Service Act. It covers proteins, antibodies, peptides, cell + gene therapies, vaccines, blood products. Approval grants 12 years of data exclusivity (longer than small molecules). Biosimilar competition arrives via 351(k) filings under the Biologics Price Competition and Innovation Act (BPCIA), 2009.
Why the exclusivity periods differ
Biologics development costs more + takes longer than small molecules (often 14-15 years vs 10-12). Congress reasoned that the higher cost justifies longer exclusivity to incentivise development. Critics argue 12 years is too long — generic small-molecule patents typically lapse before then.
Post-approval competition
NDAs face ANDA competition almost immediately at patent expiry. BLAs face biosimilar competition that's harder to mount (development cost $100-300M vs $1-5M for ANDA) and typically achieves smaller discounts (15-35% vs 60-90% for small-molecule generics). This is why biologics retain blockbuster status longer post-cliff than small-molecule drugs.
Decision criteria for sponsors
You don't choose NDA vs BLA — the FDA does based on the drug's molecular nature. Small molecules → NDA. Biologics → BLA. The only "choice" is in modality selection during early development (do you pursue a small-molecule or antibody for a given target?), which factors in IP economics, manufacturing complexity, and competitive dynamics.
FAQ
What's the difference between an NDA and an ANDA?
NDA is the original full filing for a new drug — requires complete preclinical + clinical data. ANDA (Abbreviated NDA) is for a generic version — requires only bioequivalence + identical chemistry, no clinical efficacy data. ANDAs typically approve in 18-24 months vs 10 months for NDAs.
Can a drug be approved via both NDA + BLA?
No — each molecule has a single filing pathway based on its biophysical nature. Some grey-area products (oligonucleotides, hormones) have been historically reviewed via NDA but are now typically BLA.
What's a 505(b)(2) NDA?
A "hybrid" pathway under section 505(b)(2). Sponsors can rely partially on the FDA's prior finding of safety + efficacy for a previously-approved drug, supplementing with new data for a new indication, new formulation, or new dosing. Lower cost than full NDA.
Why are biologics so expensive?
Manufacturing complexity (living cells, fermentation, purification), longer development cycles, and 12-year data exclusivity all enable + sustain higher prices. Biosimilar competition arrives slower than small-molecule generics.